Azenta Reports Steep Q2 Loss, $149M Goodwill Impairment, and Cuts Full-Year Guidance
Summary
Azenta, Inc. reported a significantly wider Q2 operating loss of $165.8 million, including a $149 million goodwill impairment charge, and substantially lowered its full-year fiscal 2026 revenue and Adjusted EBITDA margin guidance.
Key Events
-
Steep Q2 Operating Loss
Reported a GAAP operating loss of $165.8 million for Q2 FY2026, a significant increase from $18.2 million in the prior year, driven by execution gaps and a cautious demand environment.
-
$149 Million Goodwill Impairment
Recognized a substantial non-cash goodwill impairment charge of $149 million, primarily affecting the Multiomics and Sample Management Solutions reporting units, indicating a re-evaluation of asset values.
-
Substantial Full-Year Guidance Cut
Lowered fiscal 2026 revenue guidance to $603-$621 million (from prior 3-5% growth) and adjusted EBITDA margin expectations, reflecting reduced organic growth and profitability.
-
Long-Range Plan Extended
The timeline for achieving long-range plan targets has been extended by one year, from 2028 to 2029, in connection with the revised 2026 outlook.
Analysis
The Q2 FY2026 results for Azenta, Inc. are highly concerning, marked by a dramatic increase in operating loss to $165.8 million, primarily due to a $149 million non-cash goodwill impairment charge. This impairment suggests a significant re-evaluation of the value of acquired assets, particularly in the Multiomics and Sample Management Solutions segments, indicating underperformance relative to prior expectations. The company also significantly lowered its full-year fiscal 2026 guidance for both revenue and Adjusted EBITDA margin, signaling a deteriorating demand environment and execution challenges. Furthermore, the extension of the long-range plan timeline by a year underscores a slower path to achieving strategic targets. The failure to close the B Medical Systems divestiture due to the buyer's financing issues adds further uncertainty and risk. These combined factors present a very negative outlook for Azenta, impacting investor confidence and suggesting continued operational headwinds.
At the time of this filing, AZTA was trading at $23.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.87 to $41.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.